Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives

IF 0.6 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2020-11-01 DOI:10.2217/fnl-2020-0012

C. Correll, K. Demyttenaere, A. Fagiolini, G. Hajak, S. Pallanti, G. Racagni, Swaran Singh

引用次数: 4

Abstract

In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

查看原文本刊更多论文

Cariprazine治疗精神分裂症阴性症状的研究现状和未来展望

在精神分裂症中，中边缘区域的多巴胺能过度活跃，甚至可能选择性地在背侧纹状体中过度活跃，似乎会导致精神病症状的出现，而皮层区域的多巴胺能力低下是负面症状和认知缺陷的基础。管理阴性症状是目前治疗精神分裂症的一个主要挑战，缺乏解决这一临床问题的新方法。Cariprazine是一种新型的第二代抗精神病药物，专门针对主要与阴性症状相关的D3受体。综述了有关阴性症状管理和卡哌嗪治疗作用的主要问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.